Company intelligence / Profile preview
IRLAB
Gothenburg, Swedenirlab.se ↗
- Ownership
- Private
- Employees
- ~33
- Development stage
- Other
01
Overview
IRLAB has two lead compounds, mesdopetam (IRL790) and pirepemat (IRL752), both with successful Phase I and Phase IIa trials; both are in Phase IIb. A third compound, IRL757, is in Phase I. Preclinical compounds IRL942 and IRL1117 are advancing toward clinical development.[1][2][3]
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Financials
- Market cap
- $30.7M
- Total revenue
- $5.8M
- Enterprise value
- $29.7M
Beyond the preview
Go deeper on IRLAB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IRLAB.